Under a tenth of individuals eligible to benefit from GLP-1 drugs like Wegovy can access them, states the WHO as it releases its inaugural recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The latest guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant obstacles to widespread access to the injections that can assist patients in reducing considerable body mass, says the organization.
GLP-1 Therapy Scarcity
Even under the current most optimistic case, the manufacturing of such drugs might only reach about 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation urges nations and manufacturers to expand access, by approaches such as patent sharing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is scheduled to end in several countries in 2026.
How Obesity Injections Work
The injections imitate a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so users consume fewer calories.
Individuals commonly see weight reduction within a few weeks of commencing the once-weekly jabs.
Research indicates patients may see weight return within a year of discontinuing the medication, when their normal appetite come back.
To be above a healthy weight elevates your chance for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.
